Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2022
Reporting Period: The filing announces financial results for the three months ended September 30, 2022 (Q3 2022).
Key Financial Metrics
The provided text is a cover sheet and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not list specific figures within this document.
- Revenue, Profit, Cash Flow, Margins: Not provided in the filing text; contained in the referenced press release.
- Debt and Liquidity: Not provided in the filing text; contained in the referenced press release.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms the issuance of results for the period ended September 30, 2022.
Guidance, Outlook, and Management Commentary
Conference Call: Management scheduled a conference call for November 8, 2022, at 4:30 PM ET to discuss the results.
Legal Disclaimer: The information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for Q3 2022.
- Verify year-over-year growth rates and margin trends in the full press release.
- Check the conference call transcript for management's commentary on the outlook and any updated guidance.
- Confirm the status of the company's liquidity and debt obligations as detailed in the full financial statements.